

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Daratumumab + Chemotherapy Safety & Efficacy In Newly Diagnosed T-ALL & T-LL
Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
July 18, 2025
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Precursor B-Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 02, 2022
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Oregon Health and Science University | Genentech | Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
September 05, 2021
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Oregon Health and Science University | Genentech | Servier
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
SPARK-ALL: Calaspargase Pegol in Adults with ALL
Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 26, 2021
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Details : Pegaspargase is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
January 13, 2017
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : EsPhALL | National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
January 02, 2017
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : EsPhALL | National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pegaspargase is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 23, 2016
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Leadiant Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
Details : Pegaspargase is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, T-Cell.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
June 17, 2013
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Leadiant Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
